Delivery system using MAB 3E10 and mutants and/or functional fragments thereof

Abstract

A monoclonal antibody, 3E10, and active fragments thereof that selectively are transported in vivo to the nucleus of mammalian cells without cytotoxic effect are provided. The antibody and other molecules that bind to a variant of myosin IIb heavy chain found in the nucleus of skeletal muscle cells are useful as a non-viral delivery vector to target skeletal muscle in vivo. By contrast, in vitro the monoclonal antibody penetrates and is transported to the nucleus of multiple cell lines derived from different tissue types and can be used in screening tests to identify molecules that modulate growth of cells, such as cancer cells. Non-cytotoxic vectors for delivering a drug, polynucleotide or polypeptide selectively to skeletal muscle cells are also provided.

That which is claimed is: 
     
       1. A method for transporting a biologically active molecule into the nucleus of a target cell in vitro, comprising:
 a) combining said biologically active molecule in vitro with an antibody selected from the group consisting of monoclonal antibody (mAb) 3E10 as produced by a hybridoma having ATCC accession number PTA 2439 or, and an scFv fragment thereof antigen binding portion of mAb 3E10, to form an antibody-biologically active molecule conjugate or fusion protein,; and 
 b) contacting the target cell in vitro, under suitable conditions with the antibody-biologically active molecule conjugate of a), thereby transporting the biologically active molecule into the nucleus of the target cell, wherein the target cell is selected from the group consisting of a kidney cell, an ovarian cell, a bone cell, and a primary cultured neuron. 
 
     
     
       2. The method of  claim 1  wherein said biologically active molecule is a nuclear transcription factor, an enzyme, an enzyme inhibitor, genetic material, an inorganic or organic molecule, a pharmaceutical agent, a drug, or a polypeptide. 
     
     
       3. The method of  claim 2 , wherein the biologically active molecule is a polypeptide. 
     
     
       4. The method of  claim 1 , wherein the antibody is the selected from the group consisting of a single chain antibody (scFv), fragment an Fab, and an Fv. 
     
     
       5. The method of  claim 4 , wherein the biologically active molecule is a polypeptide. 
     
     
       6. The method of  claim 1 , wherein the contacting comprises incubating the cells in the presence of the conjugate or a fusion protein. 
     
     
       7. The method of  claim 1 , wherein the scFv fragment antigen binding portion of mAb 3E10 comprises the variable region of the heavy chain (VH) and variable region of the kappa light chain (Vκ) of mAb 3E10. 
     
     
       8. The method of  claim 7 , wherein the scFv fragment antigen binding portion of mAb 3E10 further comprises the signal peptide of the Vκ. 
     
     
       9. The method of  claim 1 , wherein the biologically active molecule is a p53 polypeptide. 
     
     
       10. The method of  claim 9 , A method for transporting a biologically active molecule into the nucleus of a target cell in vitro, comprising:
 a) combining the biologically active molecule in vitro with an antibody selected from the group consisting of monoclonal antibody (mAb) 3E10 as produced by a hybridoma having ATCC accession number PTA 2439, and an antigen binding portion of mAb 3E10, to form an antibody-biologically active molecule conjugate or fusion protein; and 
 b) contacting the target cell in vitro, wherein the target cell is a cancer cell, under suitable conditions with the antibody-biologically active molecule conjugate of a), thereby transporting the biologically active molecule into the nucleus of the target cell. 
 
     
     
       11. The method of claim 10, wherein the antibody is selected from the group consisting of a single chain antibody (scFv), an Fab, and an Fv. 
     
     
       12. The method of claim 10, wherein the biologically active molecule is a p53 polypeptide.